Skip to main contentSkip to navigationSkip to search
Curasight

Press releases

2022

Year-end report October - December 2021

February 24, 2022
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the Year-end report for the period October 1 – December 31, 2021. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight expands its strategy and strengthen its position as a theranostic company

February 23, 2022
 | Regulatory
Copenhagen, Denmark, 23 February 2022 - Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic company.

Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS

February 10, 2022
 | Regulatory
Copenhagen, Denmark, 10 February 2022 - Curasight A/S (“Curasight” or the “Company”) has today signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS.  Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform. 

Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy

January 27, 2022
 | Regulatory
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The study demonstrates strong prognostic value and that uPAR is expressed in the majority of neuroendocrine tumor patients. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/35058319/).

Curasight presents at the SEB Nordic Healthcare Seminar 2022 and at Kapital Partner

January 18, 2022
 | Regulatory
Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær has been invited to present at SEB Nordic Healthcare Seminar 2022 which will take place 18 January 2022. Furthermore, Curasight will present a Deep Dive event in Head and Neck cancer at Kapital Partner, 20 January 2022.

2021

Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital

December 30, 2021
 | Regulatory
Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær has been invited to J.P. Morgan 40[th] Annual Healthcare Conference which will take place 10-13 January 2022. Furthermore, Curasight will present a Deep Dive event in Brain cancer at HC Andersen Capital, 19 January 2022.

Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)

December 21, 2021
 | Regulatory
Copenhagen, Denmark, 21 December 2021 - Curasight A/S (“Curasight” or the “Company”) appoints Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug Development and Regulatory Affairs activities in the Company.

Transaction with shares in Curasight A/S made by managerial employee

December 14, 2021
 | Regulatory
COPENHAGEN – Curasight A/S (“Curasight” or “the Company”).  In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transaction made in Curasight made by managerial employee. 

Curasight presents at HC Andersen Capital

December 13, 2021
 | Regulatory
Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present a Deep Dive event in Prostate Cancer at HC Andersen Capital, 15 December 2021.

Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients

December 9, 2021
 | Regulatory
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet and using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/34857658/).
Load more